CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

Three ways you can design better drug trials for schizophrenia therapeutics

To date, no effective drugs have been developed to address cognitive dysfunction in schizophrenia. Here we will highlight the three main methodological challenges which may be contributing to these high failure rates, and propose potential practical solutions to these problems.                                                                                                                                                                                                  

A solution for improving recruitment into early Alzheimer’s disease clinical trials

Screening patients into early stage Alzheimer’s trials can be costly and time-consuming. Kenton Zavitz, PhD, Director of Clinical Affairs proposes a potential solution for improving recruitment into clinical trials. 

CANTAB Recruit software to be used in two major Phase III drug trials

​We’re pleased to announce that our CANTAB Recruit software is now established in two major Phase III trials into Alzheimer’s disease.

Join us at SIRS 2018

Cambridge Cognition are attending the Schizophrenia International Research Society Conference (SIRS): 4th - 8th April 2018

WEBINAR: Finding the right patients for clinical trials in early Alzheimer's disease

Dr Kenton Zavitz, Director of Clinical Affairs at Cambridge Cognition, and Dr Robert Smith, Consultant Neuropsychologist, hosted a webinar to discuss clinical trials for early Alzheimer’s disease.

Join them to hear more about overcoming the barriers to expedite the drug development process.

Tuesday 22nd May 2018, 11 a.m. EDT

Speech recognition and online assessments: the future for clinical trials in Alzheimer's disease?

New data demonstrates possibility for speech recognition and online assessments to enhance clinical trials in Alzheimer’s disease.

Pre-Screening for Episodic Memory Deficits To Enrich Recruitment in Alzheimer's Disease Trials

Identifying participants in the ‘pre-clinical’ or ‘prodromal’ stage of Alzheimer's disease prior to the onset of cognitive and functional decline can be challenging, time-consuming and expensive. Can, pre-screening for episodic memory deficits enrich the recruitment of eligible participants in early Alzheimer’s disease clinical trials?

Enriching Recruitment Through Identification of Episodic Memory Deficits at Pre-Screening

Dr Rosemary Abbott presented this poster at the International Conference on Alzheimer's & Parkinson's Disease on the 31st March 2017.